Tags

Type your tag names separated by a space and hit enter

Content of ecstasy in the Netherlands: 1993-2008.
Addiction. 2009 Dec; 104(12):2057-66.A

Abstract

AIMS

The present paper outlines the results of analyses carried out on the content of tablets sold as ecstasy, collected in the Netherlands by the Drugs Information Monitoring System (DIMS) from January 1993 to December 2008.

METHODS

During a period of 16 years, the DIMS analysed the content of 33 006 tablets sold as ecstasy that were handed in by numerous individual (potential) substance users. The DIMS results were compared with the results from various seized tablets to determine whether the DIMS is a monitor of the ecstasy consumer market.

RESULTS

The DIMS system appears to be a market monitor that gives an accurate reflection of what is actually available on the hidden Dutch ecstasy market. During 16 years of monitoring, the purity [tablets containing only 3,4-methylenedioxymethamphetamine (MDMA)] was lowest around 1997. During this time-period many tablets contained other substances in addition to or instead of MDMA [e.g. 3,4-methylene-dioxyamphetamine (MDA), 3,4-methylene-dioxyethylamphetamine (MDEA) and N-methyl-a-(1,3-benzodixol-5-yl)-2-butamine (MBDB), amphetamine and caffeine]. From 1998 to 2008, the number of high-dose tablets (> or =106 mg MDMA per tablet) gradually increased. The same holds true for the proportion of tablets that contained only MDMA, reaching the highest levels in 2000 and 2004. After 2004, the purity of ecstasy tablets decreased again, caused mainly by a growing proportion of tablets containing meta-chlorophenylpiperazine (mCPP).

CONCLUSIONS

The DIMS results provide valuable qualitative information on the content of ecstasy tablets in the Netherlands, and its changes throughout the years. Moreover, the results were used for national and international risk assessments and important warning and prevention activities.

Authors+Show Affiliations

Department of Drug Monitoring, Program Drug Information and Monitoring System, Trimbos Institute (Netherlands Institute for Mental Health and Addiction), Utrecht, the Netherlands. nvogels@trimbos.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19804461

Citation

Vogels, Neeltje, et al. "Content of Ecstasy in the Netherlands: 1993-2008." Addiction (Abingdon, England), vol. 104, no. 12, 2009, pp. 2057-66.
Vogels N, Brunt TM, Rigter S, et al. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009;104(12):2057-66.
Vogels, N., Brunt, T. M., Rigter, S., van Dijk, P., Vervaeke, H., & Niesink, R. J. (2009). Content of ecstasy in the Netherlands: 1993-2008. Addiction (Abingdon, England), 104(12), 2057-66. https://doi.org/10.1111/j.1360-0443.2009.02707.x
Vogels N, et al. Content of Ecstasy in the Netherlands: 1993-2008. Addiction. 2009;104(12):2057-66. PubMed PMID: 19804461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Content of ecstasy in the Netherlands: 1993-2008. AU - Vogels,Neeltje, AU - Brunt,Tibor M, AU - Rigter,Sander, AU - van Dijk,Peter, AU - Vervaeke,Hylke, AU - Niesink,Raymond J M, Y1 - 2009/10/05/ PY - 2009/10/7/entrez PY - 2009/10/7/pubmed PY - 2010/3/18/medline SP - 2057 EP - 66 JF - Addiction (Abingdon, England) JO - Addiction VL - 104 IS - 12 N2 - AIMS: The present paper outlines the results of analyses carried out on the content of tablets sold as ecstasy, collected in the Netherlands by the Drugs Information Monitoring System (DIMS) from January 1993 to December 2008. METHODS: During a period of 16 years, the DIMS analysed the content of 33 006 tablets sold as ecstasy that were handed in by numerous individual (potential) substance users. The DIMS results were compared with the results from various seized tablets to determine whether the DIMS is a monitor of the ecstasy consumer market. RESULTS: The DIMS system appears to be a market monitor that gives an accurate reflection of what is actually available on the hidden Dutch ecstasy market. During 16 years of monitoring, the purity [tablets containing only 3,4-methylenedioxymethamphetamine (MDMA)] was lowest around 1997. During this time-period many tablets contained other substances in addition to or instead of MDMA [e.g. 3,4-methylene-dioxyamphetamine (MDA), 3,4-methylene-dioxyethylamphetamine (MDEA) and N-methyl-a-(1,3-benzodixol-5-yl)-2-butamine (MBDB), amphetamine and caffeine]. From 1998 to 2008, the number of high-dose tablets (> or =106 mg MDMA per tablet) gradually increased. The same holds true for the proportion of tablets that contained only MDMA, reaching the highest levels in 2000 and 2004. After 2004, the purity of ecstasy tablets decreased again, caused mainly by a growing proportion of tablets containing meta-chlorophenylpiperazine (mCPP). CONCLUSIONS: The DIMS results provide valuable qualitative information on the content of ecstasy tablets in the Netherlands, and its changes throughout the years. Moreover, the results were used for national and international risk assessments and important warning and prevention activities. SN - 1360-0443 UR - https://www.unboundmedicine.com/medline/citation/19804461/Content_of_ecstasy_in_the_Netherlands:_1993_2008_ L2 - https://doi.org/10.1111/j.1360-0443.2009.02707.x DB - PRIME DP - Unbound Medicine ER -